Tvardi Therapeutics Q1 net loss narrows

Tvardi Therapeutics

08/05/2026 12:11

Overview

US biopharma firm's Q1 net loss narrowed yr/yr

R&D and G&A expenses rose due to higher development and personnel costs

Company expects cash runway to fund operations through clinical readouts and into Q4 2026

Outlook

Tvardi expects cash runway to fund operations through clinical readouts and into Q4 2026

Result Drivers

HIGHER R&D SPENDING - Increased research and development expenses were mainly due to higher TTI-109 development costs, partly offset by lower TTI-101 clinical costs

RISING ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher personnel costs, including stock-based compensation, and professional fees related to being a public company

Company press release: ID:nGNX4pj6kZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$6.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $8.00, about 90% above its May 7 closing price of $4.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)